Emerging Markets Earnings Roundup: Eli Lilly, Roche (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly says emerging markets remain a growing focus as it navigates sliding sales for key products in developed markets due to patent expirations. Roche looks to patient access programs again as biosimilar competition threats grow.
You may also be interested in...
Roche Moves Cancer Immunotherapy Program Into New Tumor Type
Roche’s cancer portfolio drove 2013 sales, and management said it is taking an aggressive approach to developing the “next generation of cancer therapy”: cancer immunotherapy.
Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical
The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.
List Ahead For Southeast Asia Pharma In 2015
PharmAsia News looks ahead at 2015 to highlight expected trends and events shaping the biomedical community in Southeast Asia.